| Date | Title | Description |
| 16.11.2025 | Scripta Therapeutics Transforms Disease Treatment with $12M Investment | Scripta Therapeutics, an Oxford-based techbio startup, has raised $12 million in seed funding. This capital propels its innovative biology-first platform. The system leverages AI, advanced imaging, and patient-derived models. It precisely t... |
| 14.11.2025 | Scripta Therapeutics Raises $12M in Seed Funding | Scripta Therapeutics, an Oxford, UK-based techbio startup, raised $12m in seed funding.
The round was led by Oxford Science Enterprises and Apollo Health Ventures, with participation from AlbionVC, YZR Capital, and Parkwalk Advisors, and su... |
| 12.11.2025 | The UK’s Scripta Therapeutics raises over €10 million to “flip the script” on drug discovery | Oxford BioTech startup Scripta Therapeutics emerges from stealth today by announcing a €10.3 million ($12 million) Seed round to upend conventional approaches to drug discovery.
The round is led jointly by Oxford Science Enterprises (OSE) a... |
| 24.04.2025 | SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy | Newly Appointed Board Chair, Philip Astley-Sparke, Brings Transatlantic Late-Stage Development, Regulatory and Commercial Expertise
Strengthened Leadership and Expanded U.S. Presence Positions SynOx for Regulatory Filings and Commercializat... |
| 24.04.2025 | SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) | DUBLIN, Ireland and OXFORD, United Kingdom, April 14, 2025 (GLOBE NEWSWIRE) — SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today ... |
| 13.01.2025 | Forbion promotes Dirk Kersten to Managing Partner and strengthens US team | • Dirk Kersten promoted to Managing Partner, further strengthening firm’s leadership
• Jonathan McNeill, M.D. joins Forbion as Partner in the Boston office
Naarden, The Netherlands – 13 January 2025 - Forbion, a leading global life sciences... |
| 22.12.2024 | SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial | Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors
Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1 Receptor Targeted Antibody, for the Treatment... |
| 31.10.2024 | SynOx Therapeutics: A New Dawn in Cancer Treatment | In the world of biopharmaceuticals, every breakthrough feels like a beacon of hope. SynOx Therapeutics, a late clinical-stage company based in Dublin and Oxford, has recently raised a staggering $92 million in its Series B financing round. ... |
| 30.10.2024 | SynOx Therapeutics Raises Additional Funding in Series B Round; Total to $92M | SynOx Therapeutics, a Dublin, Ireland- and Oxford, UK-based late clinical-stage biopharmaceutical company developing a novel treatment for CSF-1 related and macrophage-driven disorders, raised additional funding in Series B round.
The round... |
| 30.10.2024 | Dublin-based SynOx adds new capital to Series B, raising total to €84.8 million | SynOx, a late clinical-stage biopharmaceutical company developing a novel treatment for CSF-1 related and macrophage-driven disorders, announced that it has raised additional funding in a final close of its Series B financing. The Series B ... |
| 30.10.2024 | SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial | Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors
Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1 Receptor Targeted Antibody, for the Treatment... |
| 07.09.2024 | SynOx Therapeutics: Pioneering a New Era in Cancer Treatment | In the world of biopharmaceuticals, innovation is the lifeblood. SynOx Therapeutics, a late-stage clinical company based in Dublin and Oxford, is making waves with its promising drug, emactuzumab. This monoclonal antibody targets Tenosynovi... |
| 07.09.2024 | SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT | Dublin, Ireland and Oxford, UK, 22 April 2024: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a $75m Series B financing. The financing was co-led... |
| 07.09.2024 | SynOx Therapeutics secures up to $35m debt financing with Hercules Capital | • SynOx is developing emactuzumab – a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody
• Provides flexible loan facility to support additional clinical work and activities to drive its successful registration ... |
| 30.04.2024 | SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab | • SynOx is developing emactuzumab - a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody
• Provides flexible loan facility to support additional clinical work and activities to drive its successful registration ... |
| 30.04.2024 | SynOx Therapeutics Raises Up To $35M in Debt Financing | SynOx Therapeutics Limited, a Dublin, Ireland- and Oxford, UK-based late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases, raised up to $35M in Deb... |
| 23.04.2024 | SynOx Therapeutics: Revolutionizing TGCT Treatment with Emactuzumab | SynOx Therapeutics Limited, a clinical biopharmaceutical company, has secured a whopping $75 million in Series B financing to advance the development of Emactuzumab, a groundbreaking monoclonal antibody for the treatment of Tenosynovial Gia... |
| 22.04.2024 | Forbion co-leads $75m Series B Financing in SynOx Therapeutics | •Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures
•Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for Tenosynovial Giant Cell Tumour
Dublin, Ireland and Oxford, UK, 22 Apri... |
| 22.04.2024 | SynOx Therapeutics Raises $75M in Series B Funding | SynOx Therapeutics, a Dublin, Ireland and Oxford, UK-based late-stage clinical biopharmaceutical company, closed a $75m Series B financing.
The round was co-led by Forbion, HealthCap and new investor Bioqube Ventures. As part of the Series ... |
| 01.09.2022 | Emactuzumab designated as an Orphan Medicinal Product in Europe | Dublin, Ireland, 31 August 2022: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company, announces a regulatory update on emactuzumab, in development for the treatment of Tenosynovial Giant ... |
| 12.01.2022 | SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer | Dublin, Ireland, August 3, 2021: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumours (TGCT), today announces th... |
| 19.11.2020 | SynOx raises €37M to advance ex-Roche drug in rare tumor type | SynOx Therapeutics has raised €37 million ($44 million) to advance a drug licensed from Roche. The series A tees SynOx up to build on signs the anti-CSF1R monoclonal antibody improves outcomes in patients with tenosynovial giant cell tumors... |
| 19.11.2020 | SynOx Therapeutics raises €37M in Series A Financing | DUBLIN, Nov. 19, 2020 /PRNewswire/ — SynOx Therapeutics Ltd (“SynOx”), a clinical stage bio pharmaceutical company, announces today the closing of a €37 million Series A financing co-led by HealthCap and Medicxi and joined by investors Forb... |
| - | SynOx Therapeutics raises €37M in Series A Financing | Dublin, Ireland, November 19, 2020 –SynOx Therapeutics Ltd (“SynOx”), a clinical stage biopharmaceutical company, announces today the closing of a €37 million Series A financing co-led by HealthCap and Medicxi and joined by investors Forbio... |
| - | SynOx Therapeutics | “Synox | Website – Synox | Website” |
| - | SynOx Therapeutics: $35 Million In Debt Financing Raised From Hercules Capital | SynOx Therapeutics, a late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases, announced it has entered into a $35 million loan facility with Hercule... |
| - | SynOx Therapeutics: Clinical Biopharmaceutical Company Raises $75 Million To Develop Emactuzumab | SynOx Therapeutics Limited – a late-stage clinical biopharmaceutical company – announced today the closing of a $75 million Series B financing. The funding was co-led by Forbion, HealthCap, and new investor Bioqube Ventures.
The proceeds of... |
